With respect to assay development, quality assurance and, ultimately, clinical adoption, the primary subject of this review, these advantages are critical. Implicit with these advantages, TMAs enable ...
EYSINS, Switzerland, April 3, 2025 /PRNewswire/ --Today, AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results